Correlation Between UroGen Pharma and Indaptus Therapeutics

Can any of the company-specific risk be diversified away by investing in both UroGen Pharma and Indaptus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining UroGen Pharma and Indaptus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between UroGen Pharma and Indaptus Therapeutics, you can compare the effects of market volatilities on UroGen Pharma and Indaptus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in UroGen Pharma with a short position of Indaptus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of UroGen Pharma and Indaptus Therapeutics.

Diversification Opportunities for UroGen Pharma and Indaptus Therapeutics

0.45

Correlation Coefficient

UroGen Pharma  Indaptus Therapeutics

Very weak diversification

The 3 months correlation between UroGen and Indaptus is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding UroGen Pharma and Indaptus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Indaptus Therapeutics and UroGen Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on UroGen Pharma are associated (or correlated) with Indaptus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Indaptus Therapeutics has no effect on the direction of UroGen Pharma i.e., UroGen Pharma and Indaptus Therapeutics go up and down completely randomly.

Pair Corralation between UroGen Pharma and Indaptus Therapeutics

Given the investment horizon of 90 days UroGen Pharma is expected to generate 0.66 times more return on investment than Indaptus Therapeutics. However, UroGen Pharma is 1.52 times less risky than Indaptus Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Indaptus Therapeutics is currently generating about -0.13 per unit of risk. If you would invest  1,119  in UroGen Pharma on September 16, 2024 and sell it today you would earn a total of  16.00  from holding UroGen Pharma or generate 1.43% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

UroGen Pharma  vs.  Indaptus Therapeutics

UroGen Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Indaptus Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with UroGen Pharma and Indaptus Therapeutics

The main advantage of trading using opposite UroGen Pharma and Indaptus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if UroGen Pharma position performs unexpectedly, Indaptus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will offset losses from the drop in Indaptus Therapeutics' long position.

The idea behind UroGen Pharma and Indaptus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.